Loading…
Chinese medical-device company; specific product focus not independently confirmed with confidence.
Chinese medical-device company; specific product focus not independently confirmed with confidence.
Moat: none
Headquarters: China · Employees: 1,057
Size Caina Technology (301122.SZ) is a China Health Care company (Medical Specialties) with a market value of $938M, the 2433rd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥51.14 on 6 Nov 2026.
Performance Over six months the shares gained 60.3%, against -18.7% for the median peer and -16.4% for the China market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 61.4% over the last twelve months (peer median +4.1%); the operating margin is 0.3% (peer median 9.6%).
Valuation It trades at 72.0× forward earnings against a peer median of 23.6× (4th most expensive of 17).
Capital Return on invested capital runs 7.0 points below its cost of capital (10.0% WACC).
Next results Next results expected around 13 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥551M | CN¥355M | CN¥387M | CN¥410M | CN¥463M |
| Revenue growth | — | -8% | -6% | -12% | — |
| Gross profit | CN¥174M | CN¥71.9M | CN¥136M | CN¥154M | CN¥183M |
| EBITDA | n/a | CN¥52.5M | CN¥64.3M | CN¥123M | CN¥162M |
| Net income | CN¥13.5M | CN¥5.62M | CN¥53.1M | CN¥113M | CN¥162M |
| Free cash flow | -CN¥66.8M | -CN¥64.5M | CN¥22.0M | -CN¥91.7M | -CN¥26.0M |
| Capital expenditure | CN¥76.4M | CN¥92.7M | CN¥102M | CN¥198M | CN¥165M |
| Total debt | CN¥167M | CN¥31.4M | CN¥35.4M | CN¥429,469 | CN¥455,912 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301122.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -22.5% | -4.8% | lowest of 21 |
| 6-month return | +60.3% | -18.7% | 2nd highest of 21 |
| Distance from 52-week high | -28.7% | -41.3% | 7th highest of 21 |
| Revenue growth (TTM) | +61.4% | +4.1% | highest of 21 |
| Operating margin | 0.3% | 9.6% | 4th lowest of 21 |
| Forward P/E | 72.0× | 23.6× | 4th most expensive of 17 |
| ROIC minus cost of capital | -7.0 pp | +1.9 pp | 3rd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Caina Technology 301122.SZ | China | $938M | +60% | +61% | 0% | 72.0× | n/a | n/a |
| Shantou Institute of Ultrasonic Instruments 301602.SZ | China | $944M | -19% | +4% | 30% | n/a | 13.1% | +4.6% |
| Shenzhen YHLO Biotech 688575.SS | China | $950M | -20% | +3% | 12% | 37.2× | 3.1% | +12.7% |
| Kuros Biosciences KURN.SW | Switzerland | $953M | +3% | +41% | 6% | 73.8× | n/a | n/a |
| Aidite (Qinhuangdao) Technology 301580.SZ | China | $919M | -20% | +17% | 18% | 27.1× | 19.9% | +23.3% |
| Seegene 096530.KS | South Korea | $915M | +26% | +12% | 13% | 15.9× | -3.4% | -15.9% |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $915M | -30% | +36% | 14% | n/a | 47.2% | +17.1% |
| LifeTech Scientific 1302.HK | Hong Kong | $914M | -18% | +1% | 12% | 23.5× | 13.3% | +15.5% |
| Beijing Hotgen Biotech 688068.SS | China | $966M | -38% | +8% | -94% | n/a | n/a | n/a |
| Beijing SDL Technology 002658.SZ | China | $910M | -21% | -13% | 9% | 23.6× | 18.0% | +2.9% |
| Shanghai Runda Medical Technology 603108.SS | China | $909M | -25% | -12% | -2% | 25.1× | 22.2% | -0.2% |
| Mani 7730.T | Japan | $909M | -15% | +10% | 30% | 18.4× | 1.5% | +13.9% |
| Eckert & Ziegler EUZ.DE | Germany | $969M | -7% | +4% | 25% | 17.0× | 7.2% | +12.1% |
| Xiangyu Medical 688626.SS | China | $969M | -31% | 0% | 4% | 62.1× | n/a | n/a |
| HOB Biotech 688656.SS | China | $972M | -22% | +6% | 7% | 188.9× | 40.1% | +12.4% |
| Bioventus BVS | United States | $894M | +1% | +4% | 10% | 13.1× | 6.9% | +12.1% |
| Artivion AORT | United States | $985M | -20% | +16% | 7% | 3,912.9× | n/a | n/a |
| Safilo SFL.MI | Italy | $890M | +24% | -4% | 9% | 16.0× | -0.5% | +4.7% |
| Cisen Pharmaceutical 603367.SS | China | $890M | -15% | -6% | 8% | 8.3× | -12.9% | -1.3% |
| Castle Biosciences CSTL | United States | $993M | +64% | +3% | -9% | n/a | n/a | n/a |
| Modern Dental 3600.HK | Hong Kong | $871M | +19% | +12% | 22% | 8.8× | -7.0% | +11.3% |